Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells $1,927,250.68 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Gregory Weinhoff sold 73,196 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the completion of the sale, the insider owned 65,925 shares of the company’s stock, valued at $1,735,805.25. The trade was a 52.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock opened at $26.33 on Monday. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $9.60 and a 12 month high of $30.58. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The stock has a market cap of $3.85 billion, a PE ratio of -14.39 and a beta of 1.54. The business has a fifty day simple moving average of $24.69 and a 200-day simple moving average of $24.34.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. TD Waterhouse Canada Inc. bought a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Centessa Pharmaceuticals during the fourth quarter worth approximately $36,000. T. Rowe Price Investment Management Inc. boosted its position in Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after purchasing an additional 1,516 shares during the period. Wells Fargo & Company MN grew its holdings in Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares during the last quarter. Finally, Knott David M Jr bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $100,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Ratings Changes

CNTA has been the subject of a number of research reports. Wolfe Research assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 price objective for the company. Oppenheimer increased their price target on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a report on Friday, January 16th. B. Riley Financial boosted their price objective on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, December 1st. Finally, Chardan Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $39.80.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.